HKD 6.95
(0.14%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 71 Million CNY | 92.34% |
2022 | 310.89 Million CNY | 74.26% |
2021 | 178.41 Million CNY | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 135.04 Million CNY | 0.0% |
2024 Q1 | 135.04 Million CNY | -27.89% |
2023 Q4 | 187.27 Million CNY | -1.68% |
2023 Q3 | 190.47 Million CNY | -77.23% |
2023 FY | 597.98 Million CNY | 92.34% |
2023 Q2 | 836.37 Million CNY | 0.0% |
2023 Q1 | 836.37 Million CNY | 415.08% |
2022 FY | 310.89 Million CNY | 74.26% |
2022 Q4 | 162.37 Million CNY | 0.0% |
2022 Q3 | 162.37 Million CNY | 0.0% |
2021 FY | 178.41 Million CNY | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Uni-Bio Science Group Limited | 325.05 Million HKD | 78.155% |
CK Life Sciences Int'l., (Holdings) Inc. | 739.25 Million HKD | 90.395% |